These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31472294)

  • 1. Trends and Disparities in Asthma Biologic Use in the United States.
    Inselman JW; Jeffery MM; Maddux JT; Shah ND; Rank MA
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):549-554.e1. PubMed ID: 31472294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Related to Biologic Adherence and Outcomes Among Moderate-to-Severe Asthma Patients.
    Osazuwa-Peters OL; Greiner MA; Oberle A; Oakes M; Thomas SM; Bosworth H
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2355-2366. PubMed ID: 35640790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection.
    Jeffery MM; Shah ND; Karaca-Mandic P; Ross JS; Rank MA
    J Allergy Clin Immunol Pract; 2018; 6(5):1568-1577.e4. PubMed ID: 28958746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated With Asthma Biologic Prescribing and Primary Adherence Among Adults in a Large Health System.
    Gleeson PK; Morales KH; Hvisdas C; LaCava AF; Harhay MO; Rank MA; Apter AJ; Himes BE
    J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1834-1842.e4. PubMed ID: 36907354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
    Anderson WC; Szefler SJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):367-372. PubMed ID: 30703438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics.
    Jeffery MM; Inselman JW; Maddux JT; Lam RW; Shah ND; Rank MA
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2742-2750.e1. PubMed ID: 33652135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma.
    Bever A; Dunne J; Reynolds J; Waserman S; Kaplan AG; O'Keefe A; McNeilly S; Szabo SM
    Adv Ther; 2024 Apr; 41(4):1401-1418. PubMed ID: 38349560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.
    Ortega H; Hahn B; Tran JN; Bell C; Shams SA; Llanos JP
    Allergy Asthma Proc; 2019 May; 40(3):146-153. PubMed ID: 30925945
    [No Abstract]   [Full Text] [Related]  

  • 9. Asthma biologic trial eligibility and real-world outcomes in the United States.
    Lam RW; Inselman JW; Jeffery MM; Maddux JT; Shah ND; Rank MA
    J Asthma; 2022 Dec; 59(12):2352-2359. PubMed ID: 34818955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
    Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma.
    Moore WC; Panettieri RA; Trevor J; Ledford DK; Lugogo N; Soong W; Chipps BE; Carr W; Belton L; Gandhi H; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2020 Sep; 125(3):294-303.e1. PubMed ID: 32304877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.
    Takeshita J; Gelfand JM; Li P; Pinto L; Yu X; Rao P; Viswanathan HN; Doshi JA
    J Invest Dermatol; 2015 Dec; 135(12):2955-2963. PubMed ID: 26214380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
    Yun H; Xie F; Delzell E; Chen L; Yang S; Saag KG; Joseph G; Harrison D; Curtis JR
    Br J Clin Pharmacol; 2015 Dec; 80(6):1447-57. PubMed ID: 26130274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of asthma biologic use in a US claims database.
    Maddux JT; Inselman JW; Jeffery MM; Lam RW; Shah ND; Rank MA
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):648-654. PubMed ID: 33971361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of biologics for asthma treatment by allergy specialists: A questionnaire survey.
    Kuruvilla M; Ariue B; Oppenheimer JJ; Singh U; Bernstein JA
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):433-439. PubMed ID: 32629016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y; Shi N; John A
    Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prediction model for asthma exacerbations after stopping asthma biologics.
    Inselman JW; Jeffery MM; Maddux JT; Lam RW; Shah ND; Rank MA; Ngufor CG
    Ann Allergy Asthma Immunol; 2023 Mar; 130(3):305-311. PubMed ID: 36509405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equity in the usage of biologics for psoriasis in the working poor.
    Eley SJ; DeMeo DP; Korman NJ; Carroll BT
    Arch Dermatol Res; 2023 May; 315(4):1029-1031. PubMed ID: 36307556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.
    Herrinton LJ; Curtis JR; Chen L; Liu L; Delzell E; Lewis JD; Solomon DH; Griffin MR; Ouellet-Hellstom R; Beukelman T; Grijalva CG; Haynes K; Kuriya B; Lii J; Mitchel E; Patkar N; Rassen J; Winthrop KL; Nourjah P; Saag KG
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1199-209. PubMed ID: 21919113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.